

HEALTHCARE CONFERENCE 2022

BELL POTTER

Day 1: Tuesday, 8 November

8:25AM INTRODUCTION

8:30AM PRO MEDICUS (PME)

9:00AM 4DMEDICAL (4DX)

9:30AM VOLPARA HEALTH TECHNOLOGIES (VHT)

10:00AM MACH7 TECHNOLOGIES (M7T)

10:30AM EMVISION MEDICAL DEVICES (EMV)

Session 1

11:00AM MORNING TEA

11:10AM MEDICAL DEVELOPMENTS (MVP)

11:40AM NANOSONICS (NAN)

12:10PM RHINOMED (RNO)

Session 2

12:40PM LUNCH

1:10PM IMRICOR MEDICAL SYSTEMS (IMR)

1:40PM EBR SYSTEMS (EBR)

2:10PM ARTRYA (AYA)

Session 3

2:40PM AFTERNOON TEA

2:50PM NEUREN PHARMACEUTICALS (NEU)

3:20PM MESOBLAST (MSB)

3:50PM STARPHARMA (SPL)

4:20PM AFT PHARMACEUTICALS (AFP)

4:50PM PARADIGM BIOPHARMACEUTICALS (PAR)

Session 4

5:20PM WRAP-UP

HEALTHCARE CONFERENCE 2022

BELL POTTER

Day 2: Wednesday, 9 November

8:25AM INTRODUCTION

8:30AM ALCIDION (ALC)

9:00AM COGSTATE (CGS)

9:30AM MICRO-X (MX1)

10:00AM IMMUTEP (IMM)

Session 1

10:30AM MORNING TEA

10:40AM TELIX PHARMACEUTICALS (TLX)

11:10AM RADIOPHARM THERANOSTICS (RAD)

11:40AM CYCLOPHARM (CYC)

12:10PM CLARITY PHARMACEUTICALS (CU6)

Session 2

12:40PM LUNCH

1:10PM NEXT SCIENCE (NXS)

1:40PM ACTINOGEN MEDICAL (ACW)

2:10PM RHYTHM BIOSCIENCES (RHY)

Session 3

2:40PM AFTERNOON TEA

2:45PM MICROBA (MAP)

3:15PM UNIVERSAL BIOSENSORS (UBI)

3:45PM PHARMAXIS (PXS)

Session 4

4:15PM BREAK

4:20PM IMUGENE (IMU)

4:50PM KAZIA THERAPEUTICS (KZA)

5:20PM CHIMERIC THERAPEUTICS (CHM)

Session 5

5:50PM WRAP-UP

HEALTHCARE CONFERENCE 2022

BELL POTTER

Day 3: Thursday, 10 November

7:55AM INTRODUCTION

8:00AM TISSUE REPAIR (TRP)

8:30AM ORTHOCELL (OCC)

9:00AM POLYNOVO (PNV)

9:30AM AROA BIOSURGERY (ARX)

10:00AM IMPEDIMED (IPD)

Session 1

10:30AM MORNING TEA

10:40AM GENETIC SIGNATURES (GSS)

11:10AM PARAGON CARE (PGC)

11:40AM CRONOS AUSTRALIA (CAU)

12:10PM INOVIQ (IIQ)

Session 2

12:40PM LUNCH

1:10PM VAXXAS

1:40PM SALUDA MEDICAL

Session 3

2:10PM BREAK

2:15PM MEDTECH

2:45PM EVOLT IOH

3:15PM PLANET INNOVATION

3:45PM IMMIVIRX

Session 4

4:15PM AFTERNOON TEA

4:25PM VITRAFY LIFE SCIENCES

4:55PM CURVEBEAM AI

Session 5

5:25PM WRAP-UP

HEALTHCARE CONFERENCE 2022

Day 1: Tuesday, 8 November

8:30AM

PRO MEDICUS (PME)

Pro Medicus Limited engages in the development and supply of healthcare imaging software and services to hospitals, diagnostic imaging groups, and other health entities. Its leading product, the Visage 7 Enterprise Viewer, allows radiologists to view medical images from all major modalities at lightning fast speed including prior exams.

Market cap A\$5.3B

9:00AM

4DMEDICAL (4DX)

4DMedical Limited operates as a medical technology company in Australia and the US. It commercialises XV Technology, a four-dimensional lung imaging technology. The technology uses mathematic models and algorithms to convert X-ray scans into quantitative data enhancing the capacity of physicians to manage patients with respiratory and lung diseases.

Market cap A\$197.3M

9:30AM

VOLPARA HEALTH TECHNOLOGIES (VHT)

Volpara Health Technologies is a MedTech company focused on early detection of breast cancer by improving quality of screening using artificial intelligence. The company utilises technology designed to provide objective data on breast tissue density – a key risk marker for breast cancer.

Market cap A\$153.8M

HEALTHCARE CONFERENCE 2022

Day 1: Tuesday, 8 November

10:00AM

MACH7 TECHNOLOGIES (M7T)

Mach7 Technologies Limited provides enterprise imaging data sharing, storage, and interoperability for healthcare enterprises worldwide. The company offers enterprise data management solutions that enable cross-department and cross-enterprise workflows to capture, index, manage, distribute, view and analyse clinical imaging and multimedia content.

Market cap A\$129M

10:30AM

EMVISION MEDICAL DEVICES (EMV)

EMvision Medical Devices Limited, a medical device company, engages in the research, development, and commercialisation of imaging and diagnostic technology products. It is developing a portable device using electromagnetic microwave imaging for diagnosis and monitoring of stroke and other applications.

Market cap A\$104.1M

11:10AM

MEDICAL DEVELOPMENTS (MVP)

Medical Developments International Limited is a pain management and respiratory company. The company's lead product Pentrox (The Green Whistle) is an inhaled needle-free analgesic. The company also has a portfolio of respiratory products for sufferers of asthma and chronic obstructive pulmonary disease.

Market cap A\$138.1M

HEALTHCARE CONFERENCE 2022

Day 1: Tuesday, 8 November

11:40AM NANOSONICS (NAN)

Nanosonics developed and commercialised the Trophon – a device invented for the purpose of point of care infection control in the hospital or clinical setting. The Trophon provides high level disinfection of sensitive medical instruments with the first application in sonography probes targeting obstetrics and gynaecology patients.

Market cap A\$1B

12:10PM RHINOMED (RNO)

Rhinomed Limited engages in the research, development, and commercialisation of consumer and medical devices worldwide. It has identified and developed a proprietary nasal stent delivery technology protected by over 60 patents.

Market cap A\$38.6M

1:10PM IMRICOR MEDICAL SYSTEMS (IMR)

Imricor Medical Systems, Inc., a medical device company, designs, manufactures, sells, and distributes magnetic resonance imaging (MRI) compatible products for cardiac catheter ablation procedures. It also performs contract research, as well as licenses its intellectual property for use in implantable devices.

Market cap A\$43.9B

HEALTHCARE CONFERENCE 2022

Day 1: Tuesday, 8 November

1:40PM

EBR SYSTEMS (EBR)

EBR Systems is a clinical stage company that has developed its patented Wireless Stimulation Endocardially technology for the treatment of cardiac rhythm disease and to eliminate the need for cardiac pacing leads.

Market cap A\$154.2M

2:10PM

ARTRYA (AYA)

Artrya Limited operates as a medical technology company that uses artificial intelligence (AI) powered image-analysis software to enhance the detection and management of coronary heart disease. It offers Salix, a cloud-based software that uses its proprietary AI algorithms to interpret data from coronary scans and delivers findings.

Market cap A\$51.3M

2:50PM

NEUREN PHARMACEUTICALS (NEU)

Neuren Pharmaceuticals is a clinical stage drug development company focused on drugs to treat disorders of the Central Nervous System. The company's lead candidate is trofinetide. NEU has reported top line results from its Rett Phase 3 Lavender trial.

Market cap A\$874.2M

HEALTHCARE CONFERENCE 2022

Day 1: Tuesday, 8 November

3:20PM

MESOBLAST (MSB)

Mesoblast is a biotechnology company commercialising the therapeutic use of mesenchymal lineage cells (MPCs and MSCs), a kind of adult stem cell. MSB's technology allows these cells to be extracted from the bone marrow of donors, grown into therapeutic quantities and administered allogeneically.

Market cap A\$740.8M

3:50PM

STARPHARMA (SPL)

Starpharma Holdings Limited, a biopharmaceutical company, engages in the development of medical products based on proprietary polymers called dendrimers, with programs for respiratory viruses.

Market cap A\$257.3M

4:20PM

AFT PHARMACEUTICALS (AFP)

AFT Pharmaceuticals develops, licenses and distributes a range of over the counter and prescription medicines. AFT is not a mainstream drug developer even though a portion of its revenues are earned from the sale of prescription medicines.

Market cap A\$304.1M



HEALTHCARE CONFERENCE 2022

Day 1: Tuesday, 8 November

4:50PM

PARADIGM BIOPHARMACEUTICALS (PAR)

Paradigm Biopharmaceuticals is a biotechnology company focused on repurposing Pentosan Polysulfate Sodium for the treatment of Osteoarthritis in the knee. The recently completed phase II study produced some highly encouraging results that are worthy of further clinical trials.

Market cap A\$405.4M

HEALTHCARE CONFERENCE 2022

Day 2: Wednesday, 9 November

8:30AM

ALCIDION (ALC)

Alcidion Group Limited engages in the development and licensing of healthcare software products in Australia, New Zealand, and the United Kingdom. It also provides product implementation, product support and maintenance, systems integration, and data analysis services.

Market cap A\$158.5M

9:00AM

COGSTATE (CGS)

Cogstate is a neuroscience technology company that provides computerised cognitive testing & consulting services for trials and assessment tools for evaluation of cognitive impairment in patients. Utilisation of Cogstate test batteries in clinical trials has been driven by the rapidly expanding focus on potential Alzheimer's disease therapies.

Market cap A\$372.9M

9:30AM

MICRO-X (MX1)

Micro-X Limited is a hi-tech company developing and commercialising a range of innovative products for global health and security markets, based on proprietary cold cathode, carbon nanotube emitter technology.

Market cap A\$63.1M

HEALTHCARE CONFERENCE 2022

Day 2: Wednesday, 9 November

10:00AM IMMUTEP (IMM)

Immutep Limited is a clinical-stage biopharmaceutical company, focused on the development of novel immunotherapies for the treatment of cancer and autoimmune diseases. Its core technology is based on LAG-3 (lymphocyte activation gene-3) protein, a key mediator of the immune system.

Market cap A\$244.4M

10:40AM TELIX PHARMACEUTICALS (TLX)

Telix Pharmaceuticals Limited, a radiopharmaceutical company, develops molecularly targeted radiation products for the imaging and treatment of certain cancers. The company is developing a portfolio of products for unmet needs in oncology and rare diseases.

Market cap A\$1.6B

11:10AM RADIOPHARM THERANOSTICS (RAD)

Radiopharm Theranostics Limited develops radiopharmaceutical and nuclear medicine products for diagnostic and therapeutic uses.

Market cap A\$42.1M

HEALTHCARE CONFERENCE 2022

Day 2: Wednesday, 9 November

11:40AM **CYCLOPHARM (CYC)**

Cyclopharm is a medical device company operating in the specialist field of nuclear medicine. The main revenue driver is Technegas - a system indicated for functional lung imaging.

Market cap A\$140.5M

12:10PM **CLARITY PHARMACEUTICALS (CU6)**

Clarity Pharmaceuticals specialises in the development of Targeted Copper Theranostics for the imaging and treatment of selected cancers. The company has an extensive program of clinical development for imaging and cancer therapy and an extensive register of patents including 17 patent families covering its intellectual property.

Market cap A\$157.7M

1:10PM **NEXT SCIENCE (NXS)**

Next Science Ltd is a medical device company that pioneers innovative technologies to protect against biofilm formation and eradicate existing biofilms that are driving chronic infection and delaying healing. X BIO Technology is used to disrupt the biofilm's extracellular polymeric substance and exposes the bacteria, making it vulnerable.

Market cap A\$163.2M

HEALTHCARE CONFERENCE 2022

Day 2: Wednesday, 9 November

1:40PM

ACTINOGEN MEDICAL (ACW)

Actinogen Medical, Australian biotechnology company, is developing a novel therapy for neurological diseases associated with excessive cortisol in the brain including, Alzheimer's, major depression and Fragile X syndrome. Clinical trials using Xanamem, the company's lead candidate, are being undertaken to determine the effects of reducing cortisol on patients cognitive function.

Market cap A\$167M

2:10PM

RHYTHM BIOSCIENCES (RHY)

Rhythm Biosciences Limited, a transformative diagnostics company, engages in developing and commercialising of medical diagnostics technology. It is focused on developing ColoSTAT, a blood test for the early detection of colorectal cancer.

Market cap A\$248.1M

2:45PM

MICROBA (MAP)

Microba Life Sciences Limited operates as a gut microbiome analysis company in Australia. It offers Insight, a test for the metagenomic analysis of the gut microbiome; and bespoke health management solutions for partners and practitioners to improve patient care.

Market cap A\$35.1M

HEALTHCARE CONFERENCE 2022

Day 2: Wednesday, 9 November

3:15PM

UNIVERSAL BIOSENSORS (UBI)

Universal Biosensors, Inc. operates as a biosensors company primarily manufacturing products based around their unique and versatile electrochemical sensor technology. The company is also growing its commercial services laboratory, via contracts with research partners – mostly those running clinical trials.

Market cap A\$61.4M

3:45PM

PHARMAXIS (PXS)

Pharmaxis is a clinical stage drug development company targeting fibrosis and cancer indications with first class or best in class small molecule drugs in markets of high value. The company's lead asset PXS-5505 is in a multinational Phase 2 trials, with disease modifying potential in Myelofibrosis.

Market cap A\$42.8M

4:20PM

IMUGENE (IMU)

Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer.

Market cap A\$1B

HEALTHCARE CONFERENCE 2022

Day 2: Wednesday, 9 November

4:50PM

KAZIA THERAPEUTICS (KZA)

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma.

Market cap A\$26.3M

5:20PM

CHIMERIC THERAPEUTICS (CHM)

Chimeric Therapeutics Limited researches, develops, and commercialises cell therapies for cancer in Australia. The company develops CLTX CAR T cell therapy that is in Phase I clinical study for Glioblastoma; and CDH17 CAR T, which is in preclinical study for neuroendocrine tumours, as well as colorectal, pancreatic, and gastric cancer.

Market cap A\$36.6M

HEALTHCARE CONFERENCE 2022

Day 3: Thursday, 10 November

8:00AM

TISSUE REPAIR (TRP)

Tissue Repair is a clinical stage biopharmaceutical company developing a unique active ingredient that is designed for the treatment of chronic wounds and the aftercare of cosmetic procedures. The biologically active pharmaceutical ingredient (API) behaves like a decoy cell simulating a yeast infection, resulting in the stimulation of wound repair pathways.

Market cap A\$16.9M

8:30AM

ORTHOCELL (OCC)

Orthocell Limited, a regenerative medicine company, develops and commercialises cell therapies and biological medical devices for the repair and regeneration of human tendon, bone, nerve, and cartilage defects in Australia and internationally.

Market cap A\$78.9M

9:00AM

POLYNOVO (PNV)

Polynovo is a commercial stage medical device company and the key offering is the proprietary biodegradable temporising matrix that can be applied to complex wounds and severe burns. BTM has been approved and commercialised in the US, Australia, Europe with additional targeted segments including Asia & the Middle East.

Market cap A\$1.1B

HEALTHCARE CONFERENCE 2022

Day 3: Thursday, 10 November

9:30AM

AROA BIOSURGERY (ARX)

Aroa Biosurgery is a commercial stage medical device company that operates within the complex wound care and soft tissue reconstruction sector. It provides biologic medical devices through its AROA-ECM™ (extracellular matrix) platform. The biologic basis provides a scaffold environment for cellular infiltration and vascularisation to promote healing.

Market cap A\$262.2M

10:00AM

IMPEDIMED (IPD)

ImpediMed is a global company involved in the design and manufacture of medical devices employing bioimpedance spectroscopy (BIS) technologies. The company's BIS devices accurately and noninvasively measure a patient's fluid status and tissue composition to aid in the assessment and interventions for chronic diseases.

Market cap A\$123M

10:40AM

GENETIC SIGNATURES (GSS)

Genetic Signatures Limited operates as a molecular diagnostic (MDx) company internationally. It designs and manufactures a suite of real-time polymerase chain reaction-based products for detection of infectious disease. The key tests in the EasyScreen portfolio are used for the detection of respiratory and gastrointestinal infections.

Market cap A\$121.9M

HEALTHCARE CONFERENCE 2022

Day 3: Thursday, 10 November

11:10AM **PARAGON CARE (PGC)**

Paragon Care conducts its business largely within the Australian healthcare sector. The company has grown its revenue base via a combination of organic growth and acquisitions of small privately owned businesses.

Market cap A\$236.3M

11:40AM **CRONOS AUSTRALIA (CAU)**

Cronos Australia Limited operates as a medicinal cannabis company in Australia. The company has accounts with ~ 60% of pharmacies across Australia and also operates medicinal cannabis clinics (CannaDoc, CDA Health). The company distributes PEACE NATURALS brand medicinal cannabis products; develops and sells medicinal cannabis products; and operates medicinal cannabis clinics.

Market cap A\$432.4M

12:10PM **INOVIQ (IIQ)**

Inoviq is developing and commercialising an innovative portfolio of diagnostic and exosome-based solutions for the earlier detection, diagnosis, prognosis and monitoring of cancer and other diseases. Inoviq's multiomics approach has enabled the development of liquid biopsy tests to allow for this earlier and more accurate detection.

Market cap A\$50.6M



HEALTHCARE CONFERENCE 2022

Day 3: Thursday, 10 November

1:10PM

VAXXAS (PRIVATE)

Vaxxas develops and commercialises needle-free vaccine delivery system. The company's main product uses patch technology with thousands of vaccine-coated microprojections that is applied to the skin to efficiently deliver vaccine to the abundant immune cells immediately below the skin surface.

1:40PM

SALUDA MEDICAL (PRIVATE)

Saluda Medical is a global neuromodulation company focused on the development and commercialisation of data-driven, personalised therapies for patients with chronic pain. The company's main product Evoke instantaneously reads, records, and responds to the nerves' response to spinal cord stimulation to provide continually optimised therapy.

2:15PM

MEDTECH (PRIVATE)

Medtech Global is a health information technology company that provides advanced practice management software and state-of-the-art solutions that enable health professionals to provide improved care, and for patients to manage their health and well-being.

HEALTHCARE CONFERENCE 2022

Day 3: Thursday, 10 November

2:45PM

EVOLT IOH (PRIVATE)

Evolt develops body composition technology to promote health and wellness. The company's primary product Evolt 360 Body Composition Analyser uses the monitoring of electrical currents passed through the body to provide an in-depth body composition measurement.

3:15PM

PLANET INNOVATION (PRIVATE)


Planet Innovation Holdings is a healthtech innovation and commercialisation company that operates a portfolio of strategic investments in fast-growing, global healthtech companies. The company is a public unlisted, diversified technology company focused on the healthcare industry.

3:45PM

IMMVIRX (PRIVATE)

ImmVirX is focused on developing novel oncolytic immunotherapy combinations that harness the power of certain viruses to preferentially infect and kill cancer cells and induce systemic anti-tumour immune responses. The company is targeting cancers with high unmet need, including colorectal, gastric, pancreatic and ovarian cancer.

HEALTHCARE CONFERENCE 2022



BELL POTTER

Day 3: Thursday, 10 November

4:25PM

VITRAFY LIFE SCIENCES (PRIVATE)

Vitrafy is focused on revolutionising the delivery of current and emerging cellular therapies that require successful cryopreservation of sensitive biological material that to-date, have had notoriously low and inconsistent success rates. Vitrafy have developed new, patented, cold chain solutions for the advancement in biomedical cryopreservation.

4:55PM

CURVEBEAM AI (PRIVATE)

CurveBeam AI is a medical imaging company based in USA. The company combines market leading point-of-care diagnostic cone beam CT imaging solutions with artificial intelligence (AI) and deep learning AI (DLAI) expertise to deliver solutions across orthopaedics and bone health (fragility fracture prevention).

HEALTHCARE CONFERENCE 2022

Get in touch with your Bell Potter contact for conference access or call 1300 023 557.

Information relayed as part of the Conference is to be considered general investment advice only and does not constitute advice to any person. Although we believe that the advice and information which would be covered and/or provided as part of the Conference is reliable, Bell Potter Securities Limited has not independently verified information which is derived from publicly available sources, directors and management. As such, Bell Potter Securities Limited, its directors, employees and consultants do not represent, warrant or guarantee, expressly or impliedly, that the information that would be presented as part of the Conference is complete or accurate. Should you wish to consider and implement said information/advice, please assess the appropriateness of this information/advice with regard to your objectives, financial situation and needs, because the advice has not taken these factors into account. Bell Potter Securities Limited does not accept any responsibility to inform you of any matter that subsequently comes to its notice, which may affect any of the information presented to you as part of the Conference. Although we are elated to host you for another, please note that you are not under any obligation to attend the Conference.